spacer
home > epc > autumn 2002 > edc: quo vadis?
PUBLICATIONS
European Pharmaceutical Contractor

EDC: Quo Vadis?

To write about EDC in the year 2002 is a somewhat ambiguous enterprise. From a technical viewpoint, a proselyte of this still relatively new technique can be proud of the currently almost exploding number of publications on this topic, which makes him wonder what has been left to write about. On the other hand there are points which can't be stressed often enough, together with the need to take into account all the novelties in this fast-changing environment. From an economic and philosophical point of view, especially after the downturn of the so-called 'new economy' and the recent unpleasant revelations on 'creative accounting' in major companies, the need for positive information regarding the future of this industry is greater than ever. YES, Internet and information technology will revolutionise the clinical research industry, BUT they'll do it at different speeds and in different ways than may have been anticipated some two years ago.

EDC: the market

The market for software and services related to clinical trial processes is worth US$874 million, is growing at 17 per cent a year and will reach US$1.49 billion by 2004 (1). There is apparently a market of remarkable size, reflecting the worldwide interest in this form of clinical data management.

A multitude of different systems and solutions can be distinguished: proprietary systems, developed either by big (multinational) pharmaceutical corporations or contract research organisations (CROs) for their own purposes; 'off-the-shelf' solutions offered by software providers; tailor- made systems of medium-sized CROs, developed in conjunction with web programmers; adapted statistical software systems... a situation characteristic of a pioneering period. Each of these solutions has its distinguishing features.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Thomas Bart, Managing Director of eCR e-Clinical Research GmbH

Dr Thomas Bart is Managing Director of eCR e-Clinical Research GmbH. He studied Communication Science and National Economy at the Technical University of Berlin and Medicine at the University of Tübingen, graduating in 1989. His clinical experience is primarily in cardiology, with a specialisation in ECG and ABPM (ambulatory blood pressure monitoring).

In 1991 he joined F. Hoffmann-La Roche, Switzerland, to work in different roles in pharmaceutical marketing and clinical research. From 2000 to 2001 he was Medical Director of Boomerang Pharmaceutical Communications, a French agency developing web-based communication programmes for pharmaceutical companies. In addition to his engagement at e-Clinical Research, Thomas is an independent consultant to the pharmaceutical industry.

spacer
Dr Thomas Bart
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement